硫酸氢氯吡格雷原料药

Search documents
5月7日晚间重要公告一览
Xi Niu Cai Jing· 2025-05-07 10:29
Group 1: Company Performance - Wens Foodstuff's April chicken sales revenue was 2.543 billion yuan, a year-on-year decrease of 5.01% [1] - Wens Foodstuff sold 10.381 million chickens in April, a year-on-year increase of 10.87% [1] - Wens Foodstuff's average chicken selling price was 11.24 yuan/kg, a year-on-year decrease of 14.91% [1] - Zhongtong Bus's April vehicle sales volume was 1,046 units, a year-on-year decrease of 4.04% [1][2] - Kemin Food's April pig sales revenue reached 70.9048 million yuan, a year-on-year increase of 16.04% [3] - Muyuan Foods sold 6.573 million pigs in April, a year-on-year increase of 51.80% [5] - Muyuan Foods' pig sales revenue was 12.595 billion yuan in April, a year-on-year increase of 53.42% [5] - Xiamen Airport's April passenger throughput was 2.3881 million, a year-on-year increase of 7.73% [24] - Daqin Railway's April cargo transport volume was 30.62 million tons, a year-on-year increase of 0.99% [26] - Shaanxi Coal's April coal production was 14.24 million tons, a year-on-year decrease of 1.78% [28] Group 2: Industry Overview - Wens Foodstuff operates in the agriculture, forestry, animal husbandry, and fishery industry, specifically in pig farming [1] - Zhongtong Bus operates in the automotive industry, focusing on commercial vehicles [2] - Kemin Food operates in the food and beverage industry, specifically in food processing [3] - Muyuan Foods is also in the agriculture, forestry, animal husbandry, and fishery industry, focusing on pig farming [5] - Xiamen Airport is part of the transportation industry, specifically in airport operations [24] - Daqin Railway operates in the coal industry, focusing on coal mining and transportation [26] - Shaanxi Coal is also in the coal industry, focusing on coal mining and related services [28]
新天地:硫酸氢氯吡格雷原料药获准上市
news flash· 2025-05-07 08:08
Core Viewpoint - The company has received approval from the National Medical Products Administration for the raw material drug Sulfhydryl Clopidogrel, indicating compliance with Chinese drug review standards and enhancing the company's product portfolio [1] Group 1: Regulatory Approval - The company received the approval notice for Sulfhydryl Clopidogrel on May 6, 2025 [1] - The approval allows the raw material to be used in domestic formulations, expanding the company's product offerings [1] - The approval notice is valid until May 5, 2030 [1] Group 2: Product Information - Sulfhydryl Clopidogrel is a commonly used antiplatelet drug [1] - It is primarily used for the prevention and treatment of cardiovascular diseases related to atherosclerotic thrombosis [1] - The drug works by inhibiting platelet aggregation to reduce the risk of thrombosis [1]